Correction to: npj Breast Cancer https://doi.org/10.1038/s41523-023-00509-2, published online 04 February 2023
In this article the funding from ‘Veneto Institute of Oncology IOV-IRCCS “5x1000 anno di riferimento 2015—Genomica dei tumori e immunoterapia nell’era dei big data, fase 2” to VG’ was omitted. The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Dieci, M.V., Bisagni, G., Bartolini, S. et al. Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. npj Breast Cancer 9, 24 (2023). https://doi.org/10.1038/s41523-023-00532-3
Published:
DOI: https://doi.org/10.1038/s41523-023-00532-3
